These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 33965062)

  • 1. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
    Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
    Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory syncytial virus seasonality, transmission zones, and implications for seasonal prevention strategy in China: a systematic analysis.
    Guo L; Deng S; Sun S; Wang X; Li Y
    Lancet Glob Health; 2024 Jun; 12(6):e1005-e1016. PubMed ID: 38670132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
    Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
    BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
    Ren S; Chen Q; Zhang Y; Yi L; Qian C; Lu Y; Shen J; Liu X; Jiang M; Wang B; Song J; Shao X; Zhang T; Tian J; Zhao G
    Vaccine; 2024 Jan; 42(2):352-361. PubMed ID: 38057209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus seasonality and its implications on prevention strategies.
    Janet S; Broad J; Snape MD
    Hum Vaccin Immunother; 2018 Jan; 14(1):234-244. PubMed ID: 29194014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.
    Mahmud S; Baral R; Sanderson C; Pecenka C; Jit M; Li Y; Clark A
    BMC Med; 2023 Apr; 21(1):138. PubMed ID: 37038127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
    Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
    Li Y; Wang X; Blau DM; Caballero MT; Feikin DR; Gill CJ; Madhi SA; Omer SB; Simões EAF; Campbell H; Pariente AB; Bardach D; Bassat Q; Casalegno JS; Chakhunashvili G; Crawford N; Danilenko D; Do LAH; Echavarria M; Gentile A; Gordon A; Heikkinen T; Huang QS; Jullien S; Krishnan A; Lopez EL; Markić J; Mira-Iglesias A; Moore HC; Moyes J; Mwananyanda L; Nokes DJ; Noordeen F; Obodai E; Palani N; Romero C; Salimi V; Satav A; Seo E; Shchomak Z; Singleton R; Stolyarov K; Stoszek SK; von Gottberg A; Wurzel D; Yoshida LM; Yung CF; Zar HJ; ; Nair H;
    Lancet; 2022 May; 399(10340):2047-2064. PubMed ID: 35598608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.
    Cong B; Koç U; Bandeira T; Bassat Q; Bont L; Chakhunashvili G; Cohen C; Desnoyers C; Hammitt LL; Heikkinen T; Huang QS; Markić J; Mira-Iglesias A; Moyes J; Nokes DJ; Ploin D; ; Seo E; Singleton R; Wolter N; Fu Yung C; Zar HJ; Feikin DR; Sparrow EG; ; Nair H; Li Y;
    Lancet Infect Dis; 2024 Apr; 24(4):361-374. PubMed ID: 38141633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina.
    Guiñazú G; Dvorkin J; Mahmud S; Baral R; Pecenka C; Libster R; Clark A; Caballero MT
    Vaccine; 2024 Oct; 42(23):126234. PubMed ID: 39154512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
    Ares-Gómez S; Mallah N; Santiago-Pérez MI; Pardo-Seco J; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; Malvar-Pintos A; González-Pérez JM; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F;
    Lancet Infect Dis; 2024 Aug; 24(8):817-828. PubMed ID: 38701823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study.
    Li Y; Johnson EK; Shi T; Campbell H; Chaves SS; Commaille-Chapus C; Dighero I; James SL; Mahé C; Ooi Y; Paget J; van Pomeren T; Viboud C; Nair H
    Lancet Respir Med; 2021 Feb; 9(2):175-185. PubMed ID: 32971018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
    Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
    Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.
    Rietveld E; Steyerberg EW; Polder JJ; Veeze HJ; Vergouwe Y; Huysman MW; de Groot R; Moll HA
    Arch Dis Child; 2010 Jul; 95(7):493-8. PubMed ID: 20504841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of short-term exposure to air pollution on hospital admissions of young children for acute lower respiratory infections in Ho Chi Minh City, Vietnam.
    ; Le TG; Ngo L; Mehta S; Do VD; Thach TQ; Vu XD; Nguyen DT; Cohen A
    Res Rep Health Eff Inst; 2012 Jun; (169):5-72; discussion 73-83. PubMed ID: 22849236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.
    Shi T; McAllister DA; O'Brien KL; Simoes EAF; Madhi SA; Gessner BD; Polack FP; Balsells E; Acacio S; Aguayo C; Alassani I; Ali A; Antonio M; Awasthi S; Awori JO; Azziz-Baumgartner E; Baggett HC; Baillie VL; Balmaseda A; Barahona A; Basnet S; Bassat Q; Basualdo W; Bigogo G; Bont L; Breiman RF; Brooks WA; Broor S; Bruce N; Bruden D; Buchy P; Campbell S; Carosone-Link P; Chadha M; Chipeta J; Chou M; Clara W; Cohen C; de Cuellar E; Dang DA; Dash-Yandag B; Deloria-Knoll M; Dherani M; Eap T; Ebruke BE; Echavarria M; de Freitas Lázaro Emediato CC; Fasce RA; Feikin DR; Feng L; Gentile A; Gordon A; Goswami D; Goyet S; Groome M; Halasa N; Hirve S; Homaira N; Howie SRC; Jara J; Jroundi I; Kartasasmita CB; Khuri-Bulos N; Kotloff KL; Krishnan A; Libster R; Lopez O; Lucero MG; Lucion F; Lupisan SP; Marcone DN; McCracken JP; Mejia M; Moisi JC; Montgomery JM; Moore DP; Moraleda C; Moyes J; Munywoki P; Mutyara K; Nicol MP; Nokes DJ; Nymadawa P; da Costa Oliveira MT; Oshitani H; Pandey N; Paranhos-Baccalà G; Phillips LN; Picot VS; Rahman M; Rakoto-Andrianarivelo M; Rasmussen ZA; Rath BA; Robinson A; Romero C; Russomando G; Salimi V; Sawatwong P; Scheltema N; Schweiger B; Scott JAG; Seidenberg P; Shen K; Singleton R; Sotomayor V; Strand TA; Sutanto A; Sylla M; Tapia MD; Thamthitiwat S; Thomas ED; Tokarz R; Turner C; Venter M; Waicharoen S; Wang J; Watthanaworawit W; Yoshida LM; Yu H; Zar HJ; Campbell H; Nair H;
    Lancet; 2017 Sep; 390(10098):946-958. PubMed ID: 28689664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
    Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
    BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
    Mezei A; Cohen J; Renwick MJ; Atwell J; Portnoy A
    Epidemics; 2021 Jun; 35():100444. PubMed ID: 33662812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.